Latest Conference Articles

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

Patients with alcohol-associated liver disease face greater stigma than other liver disease etiologies.

Findings support a sex-specific approach to MetALD and ALD definitions and the need to incorporate binge drinking frequency into clinical risk stratification.

Ahead of ACAAI 2025, HCPLive spoke with Chovatiya on challenges in translating these promising immunologic targets into real-world clinical practice.

At ACAAI 2025, HCPLive spoke with Chovatiya on the OX40/OX40L pathway and what makes it an attractive therapeutic target over other established pathways.

Tegoprubart shows promise as a safer alternative to tacrolimus in kidney transplants, enhancing graft function with fewer side effects.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

This segment of Goff’s SDPA Fall 2025 interview features a discussion of dietary changes and sunscreen use as a means to improve skin health.

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Jonathan Barratt, MBChB, PhD, discusses 36-week atacicept data from ASN Kidney Week 2025.

In a session presented at the 2025 SDPA Fall Conference, a review was given of common genetic syndromes with cutaneous manifestations.

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

Phase 3 trial results reveal atacicept significantly reduces proteinuria in IgA nephropathy, paving the way for potential FDA approval in 2026.

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

At the 2025 SDPA Fall Conference, Laura Bush, DMSc, PA-C, presented the next iteration of an IMID and Obesity bootcamp session.

This preview of the 2025 NASPGHAN Annual Meeting highlights sessions and expert discussions on pediatric gastroenterology, hepatology, and nutrition covered by HCPLive.

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

Yu describes factors delaying EoE diagnosis and breaks down ways to improve diagnosis and care based on findings from her quality improvement initiative.

This preview of the 2025 SDPA Fall Dermatology Conference highlights different sessions and interviews covered by HCPLive.

View slated expert interviews and 5 clinical trials to watch at AASLD The Liver Meeting 2025.

Afzali details GALAXI post hoc findings on guselkumab in Crohn’s disease.

A multicenter study from NASPGHAN 2025 highlights geographic and immune-driven variations in pediatric H. pylori infection across the Americas.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

Kwatra spoke at Fall Clinical about several key highlights from his sessions discussing atopic dermatitis, prurigo nodularis, and the OX40 ligand (OX40L).

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.